NAMS NewAmsterdam Pharma Co N.V.

Overview and Growth

NewAmsterdam Pharma Co N.V. generated $22.50M of revenue in fiscal 2025, with net loss of $203.82M and an operating cash outflow of $147.78M. The $22.50M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Compared with $45.56M in fiscal 2024, revenue decreased 50.6%, a top-line contraction that reduced operating scale. On a per-share basis, diluted EPS was -$1.72, which connects the reported earnings outcome with the company’s diluted share count. A diluted share base of 118.42M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Compared with 94.36M diluted shares in fiscal 2024, the current 118.42M base was 25.5% higher. Total assets stood at $769.28M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Asset turnover was 0.03x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

Operations produced a $225.68M operating loss before non-operating and tax effects. The bottom-line result was a net loss of $203.82M after operating, financing, tax, and other recognized items. Net margin was -905.7%, reflecting a loss equal to 905.7% of reported revenue. The company reported negative EBITDA of $225.21M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. The pretax result was a loss of $203.82M, establishing the deficit before tax effects. The pretax loss equaled 905.7% of revenue, measuring the pre-tax deficit against sales. The net loss equaled 29.8% of period-end equity, showing the deficit relative to book capital. Relative to total assets, the net loss represented 26.5%. The bottom-line deficit decreased from $241.60M in fiscal 2024 to $203.82M.

Liquidity and Capital Structure

At period end, the $769.28M asset base was financed through $85.85M of liabilities and $683.43M of equity. At period end, current assets of $675.70M compared with current liabilities of $85.79M, defining the company’s short-term resource position. At 7.88x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. The company held $490.00M in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 571.2% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Book equity represented 88.8% of total assets, quantifying the balance-sheet share supported by shareholder capital. The liabilities-to-assets relationship was 11.2%, placing reported obligations against the full positive asset balance. The cash-to-assets relationship was 63.7%, comparing reported cash and equivalents with the full positive asset balance. Compared with $864.62M in fiscal 2024, the current asset base moved 11.0% and finished lower. Book equity was 9.8% lower than fiscal 2024 equity of $757.50M, showing how shareholder capital changed year over year. Cash and equivalents were 36.5% lower than fiscal 2024 cash of $771.74M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

Operating activities used $147.78M of cash, resulting in an operating cash outflow for the year. Capital spending of $246.00K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Operating cash flow and capital spending combined to leave a $148.03M cash deficit after capital spending. The free-cash-flow deficit equaled 657.8% of revenue, showing the post-investment cash shortfall relative to sales. The free-cash-flow deficit equaled 19.2% of total assets, placing the cash shortfall against the company’s resource base. The operating cash outflow narrowed to $147.78M from $158.56M in fiscal 2024.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Sep 24, 2026.